Miscellaneous
Following last week’s discussion of the prevalence of NAFLD in people with type 2 diabetes, this week we’re joined by Dr Stephen Harrison to discuss what can be done to help reduce the risk of progressing to NASH, despite there currently being no approved therapies. For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. References: Kenneally S, et al. Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review. BMJ Open Gastroenterol. 2017 Jun 1;4(1):e000139. doi: 10.1136/bmjgast-2017-000139. Koutoukidis DA, et al. Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. JAMA Intern Med. 2019 Sep 1;179(9):1262-1271. doi: 10.1001/jamainternmed.2019.2248. Erratum in: JAMA Intern Med. 2019 Sep 1;179(9):1303-1304. Blazina I, Selph S. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. Syst Rev. 2019 Nov 29;8(1):295. doi: 10.1186/s13643-019-1200-8. PMID: 31783920; PMCID: PMC6884753. Disclosures: Adv Bd/Panel: 89 Bio Ltd, Akero Therapeutics, Inc, Altimmune, Inc, Arrowhead Pharmaceuticals, Inc, Axcella Health, Inc, Civi Biopharma, Inc, Cymabay Therapeutics, Inc, Echosens North America, Inc, Foresite Labs, Llc, Galectin Therapeutics, Inc, Galmed Research & Dev, Ltd, Genfit Corp, Gilead Sciences, Inc, Hepion Pharmaceuticals, Inc, Hightide Therapeutics, Inc, Histoindex Pte. Ltd., Indalo Therapeutics, Inc, Intercept Pharmaceuticals, Inc, Madrigal Pharmaceuticals, Inc, Medpace, Inc, Metacrine, Inc, Ngm Biopharmaceuticals, Inc,Northsea Therapeutics B.v., Novartis Pharmaceuticals Corp, Novo Nordisk, Pathai, Inc, Poxel, Prometic Pharma Smt Ltd, Ridgeline Therapeutics, Sagimet Biosciences, Terns, Inc, Theratechnologies. Consultant: Akero Therapeutics, Inc, Altimmune, Inc, Axcella Health, Inc, Boston Pharmaceuticals, B Riley Fbr Inc, Canfite Biopharma Ltd, Civi Biopharma, Inc, Cymabay Therapeutics, Inc, Echosens North America, Inc, Enyo Pharma S.a., Fibronostics, Inc, Foresite Labs, Llc, Fortress Biotech, Inc, Galectin Therapeutics, Inc, Galmed Research & Dev, Ltd, Genfit Corp, Gilead Sciences, Inc, Gns Healthcare, Inc, Hepion Pharmaceuticals, Inc, Hightide Therapeutics, Inc, Histoindex Pte. Ltd., Indalo Therapeutics, Inc, Inipharm, Inc, Intercept Pharmaceuticals, Inc, Ionis, Kowa Research Institute, Inc, Madrigal Pharmaceuticals, Inc, Medpace, Inc, Metacrine, Inc, Microba Pty, Ltd, Ngm Biopharmaceuticals, Inc, Northsea Therapeutics B.v., Novartis Pharmaceuticals Corp, Novo Nordisk, Piper Sandler & Co, Poxel, Prometic Pharma Smt Ltd, Ridgeline Therapeutics, Sagimet Biosciences, Sonic Incytes Medical Corp, Terns, Inc, Viking Therapeutics, Inc Stocks: Akero Therapeutics, Inc, Cirius Therapeutics, Inc, Galectin Therapeutics, Inc, Genfit Corp, Hepion Pharmaceuticals, Inc, Histoindex Pte. Ltd., Metacrine, Inc, Ngm Biopharmaceuticals, Inc, Northsea Therapeutics B.v., Pathai, Inc This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporter has had no influence on the content of this education.